Source: https://online.epocrates.com/u/10a3747/Cymbalta
Timestamp: 2015-06-30 05:16:09
Document Index: 610943950

Matched Legal Cases: ['art 30', 'art 30', 'art 30', 'art 30', 'art: 30', 'art: 30', 'art: 30']

Cymbalta Entire Monograph - Epocrates Online
incr. suicidality risk in children, adolescents, and young adults w/ major depressive or other psychiatric disorders; weigh risk vs. benefit; in short-term studies of antidepressants vs. placebo, suicidality risk not incr. in pts >24 yo, and risk decr. in pts >65 yo; depression and certain other psychiatric disorders themselves assoc. w/ incr. suicide risk; observe all pts for clinical worsening, suicidality, or unusual behavior changes; advise families and caregivers of need for close observation and communication w/ prescriber
Dosage forms: 20,30,60 DR
[60 mg PO qd]
Max: 120 mg/day; Alt: 20-30 mg PO bid; Info: may start 30 mg PO qd x1wk if tolerability concern; doses >60 mg/day rarely more effective, may incr. ADR risk; periodically reassess need for tx; taper dose gradually to D/C; do not open cap
neuropathic pain, diabetic
Max: 120 mg/day; Info: may start 30 mg PO qd x1wk if tolerability concern; doses >60 mg/day rarely more effective, may incr. ADR risk; taper dose gradually to D/C; do not open cap
Max: 120 mg/day; Info: start 30 mg PO qd x2wk in elderly pts; may start 30 mg PO qd x1wk if tolerability concern; may incr. dose in 30 mg increments; doses >60 mg/day rarely more effective, may incr. ADR risk; periodically reassess need for tx; taper dose gradually to D/C; do not open cap
Start: 30 mg PO qd x1wk; Max: 60 mg/day; Info: some pts may respond to 30 mg/day; taper dose gradually to D/C; do not open cap
musculoskeletal pain, chronic
Start: 30 mg PO qd x1wk; Max: 60 mg/day; Info: taper dose gradually to D/C; do not open cap
hepatic impairment/cirrhosis: avoid use
Dosage forms: 20,30,60 DR generalized anxiety disorder
[7-17 yo]
Dose: 30-60 mg PO qd; Start: 30 mg PO qd x2wk; Max: 120 mg/day; Info: may incr. dose in 30 mg increments; periodically reassess need for tx; taper dose gradually to D/C; do not open cap
Cymbalta (duloxetine)+eliglustat 1 interaction Contraindicated duloxetine + eliglustatExtensive or Intermediate CYP2D6 Metabolizer: contraindicated if used concurrently w/ mod-strong CYP3A4 inhibitor, avoid combo or decr. eliglustat dose to 84 mg/day w/ weak CYP3A4 inhibitor, otherwise decr. eliglustat dose to 84 mg/day; Poor CYP2D6 Metabolizer: contraindicated if used concurrently w/ mod-strong CYP3A4 inhibitor, avoid combo w/ weak CYP3A4 inhibitor, otherwise caution advised: combo may incr. eliglustat levels, risk of adverse effects (hepatic metab. inhibited) isocarboxazid
Cymbalta (duloxetine)+isocarboxazid 1 interaction Contraindicated duloxetine + isocarboxazidcontraindicated if MAOI use w/in 14 days before or 5 days after: combo may incr. risk of serotonin syndrome (additive/synergistic effects) linezolid
Cymbalta (duloxetine)+linezolid 1 interaction Contraindicated duloxetine + linezolidcontraindicated w/in 14 days prior to or 24h after linezolid; D/C duloxetine and monitor closely if emergency use: combo may incr. risk of serotonin syndrome (synergistic effects, linezolid reversibly inhibits monoamine oxida